Join
Live feed
·
PRReleasevia Quantisnow
Vor Biopharma Inc. logo

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

ByQuantisnow·Wall Street's wire, on your screen.
VOR· Vor Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VOR (Vor Biopharma Inc.) and more on Quantisnow.